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Abstract 
Camptothecin (CPT), a molecule that shows powerful anticancer activity, is still 
not used in clinic due to its high hydrophobicity and poor active form’s stability. 
In order to solve these drawbacks, the combination between poly(anhydride) 
nanoparticles and cyclodextrins was evaluated.  
CPT-loaded nanoparticles, prepared in the presence of 2-hydroxypropyl-β-
cyclodextrin, (HPCD-NP) displayed a mean size close to 170 nm and a payload 
of 50 µg per mg (25 times higher than the one of the control nanoparticles). 
CPT was not released from nanoparticles under gastric conditions. However, 
under intestinal conditions, about 50% of the drug content was released as a 
burst, whereas the remained drug was released following a zero-order kinetic. 
Pharmacokinetic studies revealed that the CPT plasma levels, from orally 
administered nanoparticles, were high and sustained up to 48 h. The CPT oral 
bioavailability was 7-fold higher than the value obtained with the control, 
whereas its clearance was significantly lower than for the aqueous suspension. 
These observations may be directly related to a prolonged residence time of 
nanoparticles in close contact with the intestinal epithelium, the presence of the 
cyclodextrin that decreases the CPT transformation into its inactive form and 
the generation of an acidic microenvironment during the degradation of the 
poly(anhydride) that would prevent the transformation of the active lactone into 
the inactive carboxylate conformation.     
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Chemical compounds studied in this article 
Camptothecin (PubChem CID: 24360); Gantrez AN (PubChem CID: 62708); 2-
hydroxypropyl-β-cyclodextrin (PubChem CID: 44134771); β-cyclodextrin 
(PubChem CID: 444041); methyl-β-cyclodextrin (PubChem CID: 51051622). 
   
1. Introduction 
Oral chemotherapy is an attractive approach for cancer treatment because of its 
convenience, safety and patient acceptance, especially in chronic regimens 
[Borner et al., 2001; O’Neill and Twelves, 2002]. In recent studies, patients 
valued positively and expressed their preference for the oral route of 
administration since it interferes less with their daily life, giving them a feeling of 
freedom and a better quality of life [Halfdanarson and Jatoi, 2010]. Furthermore, 
oral administration avoids the discomfort of injection and can be eventually 
conducted at home. Unfortunately, for a number of anticancer drugs, their oral 
administration remains a challenge. This fact would be directly related to 
inadequate physico-chemical and stability properties as well as to the 
physiological barriers, which dramatically hamper the adequate absorption of 
such drugs.  
20(S)-camptothecin (CPT) is a cytotoxic quinoline alkaloid which possess an 
affinity to the DNA enzyme topoisomerase I. The activity of CPT would be 
mediated by its binding to this enzyme during S-phase, leading to the 
accumulation of single DNA strands, and thus, to cell death [Li et al., 2006]. 
Nevertheless its therapeutic application was (and remains to be) hindered by a 
very low solubility in aqueous media, high toxicity, and rapid inactivation through 
lactone ring hydrolysis at physiological pH conditions. In fact, CPT exists in a 
dynamic equilibrium between the closed-ring lactone moiety and the open-ring 
carboxylic acid form (Figure 1). The first form (lactone) is responsible for the 
molecule’s powerful anticancer activity, whereas the carboxylate form shows a 
reduced efficacy associated with a high toxicity [Lorence and Nessler, 2004]. 
These two forms coexist at 50% at a pH of 6.65, being the equilibrium moved 
towards the lactone form at lower pH and favoring the carboxylate open ring at 
higher pH [Wall et al., 1966]. Regrettably, the open-ring form, predominant at 
physiological pH shows less than 10% potency of the closed-ring form as 
topoisomerase I inhibitor [Sriram et al., 2005]. This fact would be related to the 
high affinity of the carboxylate form for human serum albumin, making it 
inaccessible for cellular uptake [Sun et al., 2012]. 
In order to solve these drawbacks, CPT derivatives, such as topotecan and 
irinotecan were synthesized. Both were approved for clinical use in Japan, 
Europe and USA [Oberlies and Kroll, 2004]. Although they offer the advantage 
of their better water solubility, camptothecin still shows lower IC50 against a 
variety of cancer cell lines [Thomas et al., 2004]. More recently, other 
approaches based on the use of drug delivery systems have been also 
proposed including nanoparticles [Min et al., 2008], liposomes [Watanabe et al., 
2008], micelles [Kawano et al., 2006], polymer derivatives [Weiss et al., 2013], 
and solid lipid nanoparticles [Yang et al., 1999; Martins et al., 2013]. 
Another possible strategy would be the incorporation of CPT in poly(anhydride) 
nanoparticles made from the copolymer of methylvinylether and maleic 
anhydride. In the recent past, these nanoparticles have demonstrated an 
important capability to develop adhesive interactions with the gut epithelium and 
improve the oral bioavailability of different drugs such as fluorouridine [Arbos et 
al., 2004], paclitaxel [Agüeros et al., 2010; Zabaleta et al., 2012] and 
atovaquone [Calvo et al., 2011]. In addition, these nanoparticles can be easily 
combined with different ligands and excipients in order to improve their mucus-
permeating properties and/or to modify their distribution within the 
gastrointestinal tract [Arbos et al., 2002; Calleja et al., 2014]. In this particular 
work, the combination of these poly(anhydride) nanoparticles with cyclodextrins 
has been studied. This combination may offer interesting advantages. First, the 
use of cyclodextrins facilitates the encapsulation of lipophilic drugs in polymeric 
nanoparticles increasing the resulting payload [Agüeros et al., 2010; Calvo et 
al., 2011]. Second, the presence of cyclodextrins modulates and sustains the 
release of lipophilic compounds from polymeric nanoparticles [Agüeros et al., 
2009; Penalva et al., 2015]. Third, in the particular case of camptothecin, 
cyclodextrins may improve up to 10 times the lactone form’s half-life [Kang et 
al., 2002]. In addition, some cyclodextrins (i.e., 2-hydroxypropyl-β-cyclodextrin) 
display an inherent ability to inhibit different enzymatic complexes and extrusion 
pumps localized in the intestinal epithelium  [Ishikawa et al., 2005; Zhang et al., 
2011].  
Therefore, the aim of this work was to optimize the preparative process of 
camptothecin-loaded poly(anhydride) nanoparticles combined with cyclodextrins 
as well as to evaluate the in vitro properties and in vivo capabilities of the 
developed nanoparticles to promote the oral absorption and bioavailability of 
this drug in Wistar rats. 
 
 
2. Materials and methods 
2.1. Reagents 
Poly(methyl vinyl ether-co-maleic anhydride) or poly(anhydride) (PMV/MA) 
[Gantrez® AN 119; MW 200,000] was purchased from ISP (Barcelona, Spain). 
Camptothecin (CPT) (99.0%) was supplied by 21CECpharm (London, UK). β-
cyclodextrin (β-CD) and 2-hydroxypropyl-β-cyclodextrin (HP-β-CD), pepsin and 
pancreatin were obtained from Sigma Aldrich (Germany) whereas methyl-β-
cyclodextrin (M-β-CD) and sulfopropyl-β-cyclodextrin (SP-β-CD) were from 
Cyclolab (Hungary). Acetone, ethanol, acetonitrile and trifluoroacetic acid (TFA) 
were obtained from Merck (Darmstadt, Germany). Deionized reagent water was 
prepared by a water purification system (Wasserlab, Spain). All reagents and 
chemicals used were of analytical grade.  
 
2.2. Solubility studies 
CPT solubility studies were carried out according to the Higuchi and Connors 
method [Higuchi and Connors, 1965]. An excess of CPT was added to a 
deionised aqueous solution in vials containing increasing amounts of the 
oligosaccharide (β-CD, HP-β-CD, M-β-CD or SP-β-CD). These flasks were 
sonicated for 5 minutes, sealed and shaken in a VorTemp 56TM Shaking 
Incubator (Labnet International Inc., USA) at 25°C for 72 hours. Then, samples 
were filtered (0.45 µm) and the concentration of CPT was determined by HPLC 
(see Section 2.4.2). The presence of trace amounts of cyclodextrins did not 
interfere with the assay. The assays were performed in triplicate.  
The apparent stability constants (Kc) and the stoichiometry of the camptothecin-
cyclodextrin complexes (CPT-CD) were estimated from the phase solubility 
diagrams. For AL diagrams, the apparent stability constant (Kc) of the drug-
oligosaccharide complex can be calculated as follows [Loftsson et al., 2004]: 
Kc=
slope
S0 (1-slope)
      [Eq.1] 
where S0 is the molar solubility of camptothecin in absence of cyclodextrins and 
the slope is obtained from the initial straight-line portion of the plot of 
camptothecin concentration against the cyclodextrin concentration. 
 
Moreover, the complexation efficiency (CE) was calculated from the slope of the 
linear phase of the phase-solubility diagram [Loftsson et al., 2005]: 
CE = S0 Kc =
slope
1-slope
      [Eq.2] 
  
2.3 Preparation of CPT-loaded nanoparticles 
Nanoparticles were prepared following a previous protocol [Calvo et al., 2011] 
with minor modifications. In brief, 100 mg poly(anhydride) were firstly dissolved 
in 5 mL acetone. Then, variable amounts of camptothecin and cyclodextrins 
were dispersed in this solution and the mixture was incubated at room 
temperature for variable time. Nanoparticles were formed by the addition of 
ethanol and water (1:1 v/v). The organic solvents were eliminated under 
reduced pressure (Büchi R210, Switzerland) and the resulting suspensions 
were filtered through a 0.45 µm membrane. Nanoparticles were purified twice 
by centrifugation at 27,000 x g, for 20 min in a 3K30 centrifuge (Sigma 
Centrifuges, UK). Supernatants were removed and pellets resuspended in 
water. Finally, the formulations were frozen and freeze-dried (Genesis 12EL, 
Virtis, USA) using sucrose (5% w/w) as cryoprotector. Control nanoparticles 
were prepared in the same way but in the absence of the oligosaccharide. 
The developed formulations were named as follows: SPCD-NP (CPT-loaded 
nanoparticles containing SP-β-CD), HPCD-NP (CPT-loaded nanoparticles 
containing HP-β-CD), MCD-NP (CPT-loaded nanoparticles containing M-β-CD 
and NP (CPT-loaded nanoparticles in absence of oligosaccharide). 
 
2.4 Characterization of the CPT nanoparticles 
2.4.1 Physicochemical characterization 
The mean hydrodinamic diameter of the nanoparticles and the zeta potential 
were determined by photon correlation spectroscopy (PCS) and electrophoretic 
laser Doppler anemometry, respectively, using a ZetaPlus analyzer system 
(Brookhaven Instruments Corporation, New York, USA). The diameter of the 
nanoparticles was determined after dispersion in ultrapure water (1:10) and 
measured at 25ºC by dynamic light scattering angle of 90ºC. The zeta potential 
was determined as follows: 200 µL of the same samples were diluted in 2 mL of 
a 0.1 mM KCl solution. The morphology of the nanoparticles was examined by 
scanning electron microscopy (SEM) in a Zeiss DSM940 digital scanning 
electron microscope (Oberkochen, Germany) coupled with a digital image 
system (Point Electronic GmBh, Germany). The yield of the process was 
calculated by gravimetry as described previously [Arbos et al., 2002]. 
 
2.4.2 Camptothecin content in nanoparticles 
The amount of camptothecin loaded into nanoparticles was quantified by HPLC. 
Briefly, the equipment was an Agilent model 1100 series LC and fluorescence 
detector set at excitation and emission λ of 380 and 418 nm, respectively. The 
chromatographic system was equipped with a reversed-phase 150 mm x 3 mm 
C18 Phenomenex Gemini column (particle size 5 µm) and precolumn 
(Phenomenex Security Guard C18). The mobile phase, pumped at 1 mL/min, 
consisted on a mixture 50:50 (v/v) of acetonitrile and trifluoroacetic acid 0.01% 
(v/v). The column was placed at 30ºC and the injection volume was 20 µL. 
Calibration curves were designed over the range of 0.48 and 8000 ng/mL (R2> 
0.999). The limit of quantification was calculated to be 1.3 ng/mL with a relative 
standard deviation of 4.1%. 
For analysis, nanoparticles were solubilized (1 mg/mL) with acetonitrile and 
further diluted in the same solvent (1:100 v/v). Samples were transferred into 
auto-sampler vials, capped and placed in the HPLC auto-sampler. Each sample 
was assayed in triplicate and results were expressed as the amount of 
camptothecin (in µg) per mg nanoparticles. The encapsulation efficiency (EE) 
was calculated as follows: 
 
EE(%)=(Qassociated Qinitial) x 100      [Eq.3]⁄  
where Qinitial is the initial amount of CPT added and Qassociated is the amount of 
entrapped CPT in the nanoparticles, which was calculated by HPLC. 
 
2.5. In vitro release study 
Release experiments were conducted at 37ºC using simulated gastric (SGF; pH 
1.2; pepsin 0.32% w/v) and intestinal (SIF; pH 6.8; pancreatin 1% w/v) fluids. In 
order to ensure sink conditions, both media included polysorbate 80 (1% w/v). 
Studies were performed under agitation in a Vortemp 56TM Shaking Incubator 
(Labnet International Inc., NJ, USA) after the dispersion of the nanoparticles in 
the appropriate medium. 
For each time point, 2.4 µg CPT formulated in nanoparticles were resuspended 
in 1 mL of the corresponding simulated fluid. The different formulations were 
kept in the SGF for 2 hours. Then, samples of nanoparticles were centrifuged 
and transferred to vials and incubated for 18 hours in SIF. At different points, 
sample tubes were collected, transferred to Vivaspin tubes (300,000 MWCO, 
Sartorius group, Germany) and centrifuged at 3000xg for 5 minutes. The 
amount of CPT released from the formulations was quantified by HPLC 
(calibration curves of free CPT in supernatants obtained from SGF and SIF, R2> 
0.999). 
For experiments in SIF, the data obtained after the initial burst step were fitted 
to a zero-order kinetic model (Eq. 4). This model has been suggested for drug 
delivery systems in which the matrix releases the same amount of drug by unit 
of time [Costa and Sousa Lobo, 2001]:  
Q𝑡 = Q0 + KZ0 t       [Eq.4]  
Where Qt is the amount of drug dissolved in time t and Q0 is the initial amount of 
drug in the solution (most times, Q0 = 0) and KZO is the zero-order release 
constant. We have used a modified zero-order equation, where we have 
replaced the Qt and Q0 term with Mt/M∞ (fraction of released drug at time t), 
and KZ0 is the zero order release constant. 
 
2.6. In vivo pharmacokinetic studies in Wistar rats 
Pharmacokinetic studies were performed in Wistar rats obtained from Harlan 
(Barcelona, Spain). Studies were conducted in accordance with the ethical 
guidelines and policies for investigations in laboratory animals approved by the 
Ethical Committee for Animal Experimentation of the University of Navarra 
(protocol number 058-12) in accordance with the European legislation on 
animal experiments.  Before the experiment, animals were adaptively fed for 1 
week with free access to food and drinking water (22±2ºC; 12-h light and 12-h 
dark cycles; 50-60% relative humidity). Before the oral administration of the 
formulations, animals were fasted overnight to avoid interference with the 
absorption, allowing free access to water. 
For the pharmacokinetic study, rats were randomly divided into 4 groups (n=6). 
The experimental groups, receiving a single oral dose of CPT, were as follows: 
(i) HPCD-NP 1 mg/kg, and (ii) HPCD-NP 5 mg/kg. For the administration, 
nanoparticles were dispersed in 1 mL water and the resulting suspension was 
administered orally to animals. As controls, 2 different groups of animals 
received a camptothecin suspension either intravenously (via tail vein) or orally. 
This camptothecin suspension was prepared extemporary by dispersing the 
drug (3.6 mg) in 10 mL of a solution of 10% Tween 80 and saline (9:1 by vol.) 
and sonicated for 20 minutes to breack up aggregates [Fox et al., 2009].  
Blood samples were collected at set times after administration. EDTA was used 
as anticoagulant agent. Blood volume was recovered intraperitoneally with an 
equal volume of normal saline solution pre-heated at body temperature. 
Samples were immediately placed on ice and centrifuged at 2,500xg for 10 
minutes. Plasma was separated into clean tubes and kept frozen at -20ºC until 
HPLC analysis. 
 
2.6.1. Determination of CPT plasma concentration by HPLC 
The amount of CPT was determined in plasma by HPLC and fluorescence 
detection with the technique described above (see Section 2.4.2).  The only 
difference was that the injection volume was 100 µL. In addition, calibration 
curves and quality controls were designed over the range of 0.48 and 8000 
ng/mL (R2>0.999) by adding appropriate volumes of standard camptothecin in a 
mixture of dimethylsulfoxide, acetonitrile and trifluoroacetic acid 1:8.9:0.1 (by 
vol.) to drug free plasma.  
For analysis, an aliquot (100 µL) of plasma was mixed with 400 µL of 
acetonitrile and vortexed for 2 min in order to achieve the precipitation of the 
plasma proteins. After centrifugation (5000xg, 5 min), the supernatant was 
collected and evaporated until dry (Savant, Barcelona, Spain). Finally, the 
residue was dissolved in 120 µL of reconstitution solution (dimethylsulfoxide, 
acetonitrile and trifluoroacetic acid; 1:8.9:0.1 v/v/v) and transferred to 
autosampler vials, capped and placed in the HPLC autosampler. The limit of 
quantification was calculated to be 2.6 ng/mL with a relative standard deviation 
of 4.6%. 
 
2.6.2. Pharmacokinetic data analysis 
The pharmacokinetic analysis of plasma concentration plotted against time 
data, obtained after administration of the different CPT formulations, was 
performed using a non-compartmental model with the WinNonlin 5.2 software 
(Pharsight Corporation, USA). The following parameters were estimated: 
maximal plasma concentration (Cmax), time in which Cmax is reached (Tmax), area 
under the concentration-time curve from time 0 to t (AUC), mean residence time 
(MRT), clearance (Cl), volume of distribution (V) and half-life in the terminal 
phase (t1/2). 
Furthermore, the relative oral bioavailability, Fr, of CPT was expressed as the 
ratio between the area under the concentration-time curve from time 0 to t 
(AUC) of the formulations assayed (HPCD-NP) and the one of the oral 
suspension of camptothecin administered. 
 
2.7. Hematological studies 
At the end of the pharmacokinetic study, and before the sacrifice of the animals, 
blood samples were collected in order to evaluate different hematological and 
biochemical values. The following hematological parameters were analyzed in a 
Sysmex XT1800i hematology analyzer (Roche Diagnostics Ltd., Switzerland): 
hemoglobin (HGB, g/L), hematocrit (HCT, %), red blood corpuscles count (RBC, 
1012/L), white blood corpuscles count (WBC, 109/L), absolute erythrocyte 
indices and white blood cells. On the other hand, biochemical analyses of 
plasma samples were performed with a Hitachi 911™ analyser (Roche 
Diagnostics, Switzerland), following the protocols standardized by the 
manufacturer. The following parameters were calculated: aspartate 
transaminase (AST, U/L), alanine transaminase (ALT U/L) and urea (mg/dL). 
 
2.8. Statistical analysis 
For the physicochemical and pharmaceutical characterization of formulations, 
data are expressed as the mean ± standard deviation (S.D.) of at least three 
experiments. For in vivo results, the non-parametric Kruskall-Wallis followed by 
Mann-Whitney U-test was used to investigate statistical differences. In all 
cases, P values lower than 0.05 were considered as statistically significant 
difference. All data processing was performed using GraphPad Prism 5.0 
statistical software (GraphPad Software, USA). 
 
 
3. Results 
3.1 Solubility studies 
The phase-solubility diagrams for the complex formation between camptothecin 
and the different cyclodextrins are presented in Figure 2. This plot shows that 
the solubility of the drug in water increased linearly as a function of the 
oligosaccharide concentration. For all the cyclodextrins tested, the solubility 
diagram of camptothecin can be classified as an AL type [Higuchi and Connors, 
1965]. These results would theoretically suggest the formation of a CPT-
cyclodextrin complex with a probable 1:1 stoichiometry. The apparent stability 
constants, Kc, obtained from the slopes of the linear phase solubility diagrams 
(Table 1) were found to be of about 237 M-1 (for β-CD), 130 M-1 (for HP-β-CD), 
93 M-1 (for SP-β-CD) and 453 M-1 (for M-β-CD). 
The complexation efficiency was calculated to be 0.0024, 0.0014, 0.0011 and 
0.0052 for β-CD, HP-β-CD, SP-β-CD and M-β-CD, indicating that on average, 
the water-soluble system formed by the oligosaccharide and camptothecin 
involves a molar ratio of CPT/CD of 1/400, 1/700, 1/900 and 1/200, respectively.  
 
3.2. Optimization of the preparative process of camptothecin-loaded 
nanoparticles 
As a first approach, bare poly(anhydride) nanoparticles (prepared in the 
absence of cyclodextrins) were evaluated in order to know their capability to 
load camptothecin. The resulting carriers displayed a mean size of about 130 
nm and a payload of 2.2 µg CPT per mg nanoparticles. Thus, in order to 
improve this payload, nanoparticles were prepared by incorporating 
cyclodextrins. For the optimization of the preparative process of CPT-loaded 
poly(anhydride) nanoparticles in the presence of cyclodextrins, two parameters 
were studied: (i) incubation time between the three main components of the 
formulation (drug, cyclodextrin and polymer) before the formation of 
nanoparticles by desolvation and (ii) the CPT/oligosaccharide ratio. All the 
studies were performed with an initial bulk amount of polymer of 100 mg. 
Figure 3 shows the influence of the incubation time in acetone between the 
different compounds forming the nanoparticles (HP-β-CD, CPT and the 
polymer) on the drug loading and the encapsulation efficiency of the resulting 
carriers. Surprisingly, the best results were obtained when nanoparticles were 
formed after just 1 minute of incubation between the components of the 
formulation (polymer, cyclodextrin and drug). Under these circumstances, the 
payload of the resulting nanoparticles was 50 µg CPT per mg nanoparticles. 
This amount represented 22-times more camptothecin than that observed for 
bare nanoparticles. However, longer times of incubation negatively influenced 
the CPT loading and the encapsulation efficiencies. Thus, 60 min of incubation 
between the three main components of the formulation lead to a drug loading of 
about 15 µg CPT/mg with an EE of 6%. 
The next step was to evaluate the influence of the CPT/cyclodextrin molar ratio 
on the drug loading and the encapsulation efficiency. Figure 4 summarizes 
these results. 
For a CPT/ HP-β-CD ratio of 1, the payload of the resulting nanoparticles was 
close to 50 µg/mg and similar to the value observed when a ratio of 2.4 was 
used (Figures 3 and 4). Nevertheless the encapsulation efficiency was 
significantly higher for a CPT/cyclodextrin ratio of 1 than when a ratio of 2.4 was 
used (p>0.05). When the CPT/oligosaccharide ratio was lower than 1, the CPT 
loading significantly decreased (p>0.05; Figure 4).  
For sulphopropyl-β-cyclodextrin and methyl-β-cyclodextrin based nanoparticles, 
a similar influence of the incubation time and the CPT/oligosaccharide ratio was 
found (data not shown). In addition, for the three cyclodextrins tested, when the 
amount of oligosaccharide used to prepare the nanoparticles was higher than 
18% of the polymer mass, the process resulted always in the aggregation of the 
nanoparticles.  
 
3.3. Characterization of the CPT-loaded nanoparticles 
Based on the former optimization results, nanoparticles containing cyclodextrins 
were prepared at a CPT/cyclodextrin molar ratio of 1 and with an incubation 
time (between the components of the formulation) of 1 minute. The 
physicochemical characteristics of the resulting poly(anhydride) nanoparticles 
containing CPT are summarized in Table 2. Overall, nanoparticles containing 
cyclodextrins displayed a mean size slightly higher than bare nanoparticles 
(150-170 nm vs 130 nm). Interestingly, in all cases, the polydispersity index 
(PDI) was lower than 0.2, which implies homogeneous formulations. 
Concerning the zeta potential, all nanoparticle formulations showed a negative 
surface charge; slightly lower for nanoparticles containing cyclodextrins than for 
control ones. On the other hand, the yield of the process significantly increased 
when cyclodextrins were incorporated in the preparative procedure of 
nanoparticles. In addition, nanoparticles containing HP-β-CD displayed a 
slightly higher yield than when SP-β-CD or M-β-CD were used.   
Finally, for nanoparticles containing cyclodextrins, the drug loading was 
between 17 and 25 times higher than for control nanoparticles (NP). Comparing 
the different cyclodextrin tested, nanoparticles containing HP-β-CD displayed 
the highest capability to encapsulate camptothecin into poly(anhydride) 
nanoparticles (around 50 µg/mg). 
The morphological analysis by scanning electron microscopy (Figure 5) showed 
that nanoparticles containing cyclodextrins consisted of homogeneous 
population of spherical particles, with a smooth appearance and a mean size 
similar to that obtained by photon correlation spectroscopy.  
  
3.4 In vitro release study. 
CPT release kinetics from nanoparticles was evaluated in simulated gastric and 
intestinal fluids (containing polysorbate 80 as solubilizing agent for CPT). Figure 
6 represents the release profiles of camptothecin from the different assayed 
formulations as a function of time.  Overall, all the nanoparticle formulations 
displayed a similar release behaviour. This pattern was characterised by a first 
non-release step, when nanoparticles were dispersed in SGF, and a release 
step (when nanoparticles were dispersed in SIF), in which around 50% of the 
loaded drug was rapidly released followed by a more sustained deliverance 
phase. This second phase in SIF was characterized by a continuous release of 
campthotecin for at least 15 hours. 
This release profile of camptothecin from nanoparticles containing 
cyclodextrins, after the initial burst effect, seemed to be linear and constant. 
Therefore zero order equation [Eq. 4] was fitted to the second step of the 
release curve in SIF. This sustained release of camptothecin from these 
nanoparticles was well adjusted to this model (Table 3) characterised by R2 
higher than 0.89 in all cases. 
 
3.5. In vivo pharmacokinetic studies in Wistar rats 
The plasma concentration-time profile of CPT after a single intravenous 
administration at a dose of 1 mg/kg is shown in Figure 7. Camptothecin was 
administered as a suspension with a particle size of 1500±144 nm and a PDI of 
0.44±0.05. Data were analysed by a non-compartmental model. CPT plasma 
concentration decreased rapidly after the administration, not being detectable 6 
hours after the administration. After administration, the drug plasma 
concentration reached 430 ng/mL (Cmax) and the values for AUC and t1/2z, were 
0.39 µg h/mL and 0.69 hours, respectively. The CPT clearance and the volume 
of distribution were calculated to be 755 mL/h and 683 mL, respectively (Table 
4). 
Figure 8 shows the plasma concentration profiles of CPT after the 
administration of a single oral dose (1 mg/kg or 5 mg/kg) to rats as either a 
suspension or loaded in nanoparticles. When the drug suspension was 
administered orally, the plasma levels increased rapidly reaching the Cmax 30 
min after administration. Then, sustained plasma levels of the drug were 
maintained for at least 4 hours and, finally, the CPT levels decreased rapidly. 
Thus, 10 hours after administration, not detectable levels of CPT in plasma 
were observed.  
For camptothecin-loaded in nanoparticles (HPCD-NP), and administered at the 
same dose (1 mg/kg), the main difference with the aqueous suspension 
formulation was that the drug levels were quantified in plasma for a more 
extended period of time. Thus, animals that received CPT included in 
nanoparticles showed a first phase characterized by increasing levels of drug in 
plasma for the first 0.5 to 6 hours, followed by a slow and prolonged decrease 
phase with quantifiable levels of CPT until 48 hours. This fact was confirmed 
when HPCD-NP was administered to animals at a dose of 5 mg/kg (Figure 8).  
Table 4 summarises the main pharmacokinetic parameters estimated with a 
non-compartmental analysis of the experimental data obtained after the 
administration of the different formulations to rats. The drug suspension showed 
similar AUC values when administered intravenously or orally (0.39 and 0.38 µg 
h/mL, respectively) being the Cmax 5 times higher for the intravenous route. The 
MRT was significantly higher when administered by the oral route than 
intravenously (1 hour versus 5.9 h; p< 0.01). Similarly, the volume of distribution 
was significantly higher when camptothecin was administered by the oral route 
than intravenously (p< 0.05). No statistical differences were observed for the 
clearance of camptothecin or for the half-life of the drug in the terminal phase of 
the curve. 
For HPCD-NP, the camptothecin AUC was found to be about 6.5-times higher 
than when the drug was orally administered as a suspension. In a similar way, 
the MRT was also higher when CPT was administered in the form of 
nanoparticles (31 h vs 5.9 h; p < 0.01). It is noteworthy that for HPCD-NP, the 
clearance of camptothecin was significantly lower than for the drug suspension 
(p< 0.05). This fact would be due to an important improvement of t1/2z. Besides, 
the relative oral bioavailability of camptothecin was found to be 6.9 fold higher 
when loaded in nanoparticles than when administered as oral suspension. 
Finally, for HPCD-NP administered at a dose of 5 mg/kg, the pharmacokinetic 
parameters were found to be quite similar to those calculated at a 1 mg/kg 
dose. The main difference would be the decrease observed in the relative oral 
bioavailability (6.9 vs 3.3) after the application of the dose correction. 
 
3.6. Hematological studies 
Figure 9 shows some hematological and biochemical values of the animals at 
the end of the pharmacokinetic study. The administration of CPT produced a 
significant decrease in RBC and HGB compared to the control (p<0.01). 
Furthermore, a significant decrease in white blood cells was also observed for 
animals treated orally with CPT (p<0.05). Regarding the biochemical 
parameters, the levels of AST, ALT and urea nitrogen for animals treated with 
CPT were found to be similar to that of the control (non-treated) animals. 
 
 
4. Discussion 
Camptothecin is a highly lipophilic compound with a low oral bioavailability that 
shows a low stability related with a rapid hydrolysis of its lactone ring under 
physiological conditions (t1/2 of approximately 22 min at 37ºC and pH 7.4) [Mi 
and Burke, 1994; Sun et al., 2012]. This reaction is a reversible pH-sensitive 
interconversion from the potent lactone form (stable below pH 5) to the poorly 
active, and even toxic, carboxylate form (stable above pH 8) (Figure 1) [Mi and 
Burke, 1994]. In an attempt to minimize these drawbacks, the aim of this work 
was to evaluate the capability of poly(anhydride) nanoparticles for the oral 
delivery of camptothecin when associated to cyclodextrins.  
In our experimental conditions, the phase solubility diagrams of camptothecin in 
presence of different cyclodextrins (Figure 2) can be considered as AL type, 
suggesting that the complex is hydrosoluble and formed following a 1:1 
stoichiometry. At a concentration of 1.5% w/v, β-CD (near its solubility limit in 
water) increased camptothecin’s solubility 3 times compared to that of the free 
drug (0.011mM in water). Regarding the three modified cyclodextrins tested 
(HP-β-CD, M-β-CD and SP-β-CD), at a concentration of 20% w/v, they were 
able to enhance the drug’s solubility in water by factors of 24, 67 and 22, 
respectively. These data are in accordance with those reported previously by 
other research groups that suggested that the significantly higher solubilizing 
effect of M-β-CD compared to other cyclodextrins would be attributed to the 
presence of methyl groups, which enlarge the whole cavity of the molecule by 
extending the secondary hydroxyl side and narrowing the primary hydroxyl side 
of the cone [Uekama, 1985; Kang et al., 2002]. On the other hand, the low 
complexation efficiency values calculated for all the CPT/cyclodextrin 
complexes suggested a tendency of cyclodextrins and their complexes to self-
associate by forming aggregates in aqueous media [Messner et al., 2010]. This 
phenomenon would probably be promoted by the incubation time.  
Nanoparticles were prepared by a simple desolvation method. The mean size of 
the camptothecin-loaded nanoparticles when prepared in the presence of 
cyclodextrins appeared to be slightly higher than those obtained by control 
nanoparticles. On the other hand, the incorporation of cyclodextrins resulted 
effective in improving the camptothecin payload; however, prolonging the 
incubation time between the different components of the formulation 
(oligosaccharide, drug and polymer) prior the formation of nanoparticles 
negatively affect the drug loading (Figure 3). This observation may be directly 
related to the formation of more stable CPT:cyclodextrin complexes, by 
increasing the incubation time. As a consequence, the migration of the 
drug:oligosaccharide complexes  to the aqueous phase during the formation of 
nanoparticles (by the desolvation of the polymer with the addition of ethanol and 
water; section 2.3) would be facilitated. In any case, under the selected 
experimental conditions, the incorporation of cyclodextrins increased the 
camptothecin loading up to 25 times higher than when nanoparticles were 
prepared in the absence of these oligosaccharides (Table 2). Surprisingly, in 
spite of its modest ability to increase the aqueous solubility of the drug, HP-β-
CD was found to be the most successful oligosaccharide to promote the 
camptothecin encapsulation in the poly(anhydride) nanoparticles, reaching a 
drug  loading close to 50 µg per mg nanoparticle. When M-β-CD was used 
during the preparation of nanoparticles (M-NP), the camptothecin drug loading 
was about 15% lower than when HP-β-CD was used. This fact may be due to 
the higher affinity of CPT for M-β-CD that would drag the drug to the aqueous 
phase during the formation of nanoparticles by desolvation. In any case, the 
CPT loadings (between 3.4 and 5%, Table 2) were higher than those published 
previously by other authors including PLGA nanoparticles (2.6% CPT) [Cirpanli 
et al., 2009], poly(e-caprolactone) nanoparticles (1.4%) [Cirpanli et al., 2009], or 
poly(aspartic) nanoparticles (1.96%) [Zeng et al., 2013]. 
Concerning the in vitro release of CPT from these nanoparticles, it is noteworthy 
that under acidic conditions (SGF), no drug release was observed for any of the 
formulations tested (Figure 6). However, when nanoparticles were dispersed in 
simulated intestinal fluid (neutral pH conditions), camptothecin was released. 
Under these SIF conditions, the release was characterized by a burst effect of 
about 50% of the drug content followed by continuous slow release of the 
remaining content of drug in the nanoparticles (Figure 6). This second step 
followed a zero-order kinetic (Table 3), in which CPT was released at a rate 
close to 2.5 %/h. All of these results may be directly related with the behavior of 
poly(anhydride) nanoparticles in different media. In fact, in an aqueous 
environment, the anhydride groups of the nanoparticles are hydrolyzed yielding 
two carboxylic acid residues (-COOH). When nanoparticles are in an acidic 
environment, these carboxylic acids are not ionized and the polymer would 
adopt a compact conformation, decreasing the porosity of the nanoparticles 
[Agüeros et al., 2009]. On the contrary, when the nanoparticles moved to a 
neutral aqueous medium, nanoparticles would swell due to an ionization of the 
carboxylic acids residues.  
For the pharmacokinetic study, single doses of 1 and 5 mg/kg were selected. 
Amongst all the nanoparticle formulations developed, HPCD-NP was chosen for 
the pharmacokinetic study, since it was the most successful regarding CPT 
loading. The intravenous administration of a single dose of camptothecin as a 
suspension (1 mg/kg) to laboratory animals produced initial high drug levels in 
plasma, followed by a rapid biphasic decline over time (Figure 7). Six hours 
after the administration, the plasma drug levels were close to the quantitation 
limit of the analytical technique. This profile is in accordance with previous 
results described by other authors who suggested that this rapid decline of 
plasma drug levels could be due to an embolization or retention of the drug 
particulates in the lung capillaries [Martins et al., 2013].  
When the same suspension was administered orally, the Cmax was 5-times 
lower than the iv administration; although, plasma levels decreased more gently 
and CPT was quantified up to 8 h post-administration. The CPT clearance of 
the oral suspension was similar to that calculated when administered iv; 
however, the half-life of the terminal phase was about 2.5 fold higher than when 
administered intravenously (p<0.05). For HPCD-NP (1 mg/kg), the plasma 
levels of camptothecin were high and sustained until 48 h after administration. 
For this formulation, the relative bioavailability was calculated to be 6.9-times 
higher than for the drug oral suspension. This fact would be related to the 
capability of these nanoparticles to reach the gut mucosa, prolonging their 
residence in close contact with the intestinal epithelium, in which they would 
release their cargo and, hence, facilitating the camptothecin absorption in a 
continuous way [Calleja et al., 2014]. Interestingly, the clearance of 
camptothecin, when administered as HPCD-NP, was significantly lower than for 
the suspension (p< 0.05), whereas the half-life of the terminal phase was 
calculated to be about 15-times higher when CPT was loaded in nanoparticles 
than formulated as suspension (p<0.01). Different reasons may explain this 
behavior including the prolonged residence time of nanoparticles in the 
absorptive membrane, the presence of cyclodextrin molecules that prevent the 
formation of the CPT carboxylate open-ring form [Kang et al., 2002], and the 
generation of an acidic microenvironment due to the degradation of the 
polymeric nanoparticles via hydrolysis of the poly(anhydride). As a 
consequence, CPT would be protected from its transformation into the inactive 
form till its complete release from nanoparticles, facilitating its absorption and 
arrival to the systemic circulation in the lactone conformation. 
Regarding the administration of HPCD-NP at a dose of 5 mg/kg, 
pharmacokinetic parameters were similar to those found with the same 
formulation administered at a dose of 1 mg/kg. Nevertheless, the relative 
bioavailability (adjusted to the dose) was found to be 2-times lower than that 
calculated with the low dose (1 mg/kg). This observation would be related to the 
specific mechanisms involved in the intestinal absorption of camptothecin. In 
fact, CPT is absorbed via passive diffusion and carrier-mediated active 
processes [Gupta et al., 2000]. Therefore, it is plausible to think that with the 
high dose (5 mg/kg), the intestinal transporters involved in the absorption of 
CPT would be saturated. A similar phenomenon has been proposed for other 
lipophilic compounds such as paclitaxel and some platinum complexes 
[Mckeage et al., 1995; Malingré et al., 2001].  
Finally, 48 hours after the anticancer drug administration, hematological and 
biochemical analyses were carried out. It has been reported that CPT and its 
derivatives can induce severe inhibition of marrow leading to the change of 
hematological parameters [Bülbül Hizel et al., 2008]. More particularly, CPT 
decreases red blood cells, white blood cells and platelet counts and hemoglobin 
[Singh and Marar, 2011; Luo et al., 2016]. The tested groups received the drug 
suspension (iv and oral, 1 mg/kg) and HPCD-NP (5 mg/kg). As shown in Figure 
9, in all cases, CPT caused important decreases in RBC and HGB compared 
with the non-treated animals. Similarly, when CPT was administered orally (as 
suspension or in the form of nanoparticles), the white blood cells were also 
lower than for normal rats (p<0.05). Interestingly, the group of animals receiving 
the highest dose of CPT (HPCD-NP, 5 mg/kg) exhibited similar values than the 
group of animals treated with the intravenous suspension of the anticancer drug 
(1 mg/kg). On the other hand, ALT and ASM levels are usually used to monitor 
liver diseases [Jiang et al., 2011], whereas an increase in serum urea nitrogen 
is the marker for kidney damage [Singh and Marar, 2011]. In this case, none of 
the formulations tested induced significant changes in any of these biochemical 
parameters.  
In summary, poly(anhydride) nanoparticles containing HP-β-CD were able to 
load a significant amount of camptothecin and provide gastrorresistant 
properties to the resulting formulation (HPCD-NP). After the oral administration 
of these nanoparticles to rats, the camptothecin plasma levels were high and 
sustained in time up to 2 days offering a relative oral bioavailability which was 
calculated to be at least 7 fold higher than that observed for the control. These 
plasma levels with other evidences (such as the decreased drug clearance) 
suggest that these nanoparticles would provide a long residence time in the 
intestinal mucosa and, at the same time, would be capable of protecting the 
transformation of the camptothecin lactone form to the carboxylate conformation 
that is facilitated at neutral pH conditions.  
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Figure captions 
Figure 1. Chemical structure of camptothecin in its lactone form and carboxylate 
conformation. 
 
Figure 2. Phase solubility diagrams of CPT-cyclodextrin systems in purified 
water at 25ºC. Data show the amount of camptothecin solubilised as a function 
of the amount of cyclodextrin in the medium. β-CD: β-cyclodextrin; HP-β-CD: 
hydroxypropyl-β-cyclodextrin; SP-β-CD: sulfopropyl-β-cyclodextrin; M-β-CD: 
methyl-β-cyclodextrin. Data expressed as mean±SD, n=3. 
 
Figure 3. Influence of the incubation time between the components of the 
formulation (polymer, cyclodextrin and drug in acetone) before the formation of 
nanoparticles on the camptothecin loading (bars, left axis) and encapsulation 
efficiency (line, right axis). NI: 1 min of incubation. Experimental conditions: 
CPT/cyclodextrin molar ratio of 2.4; polymer 100 mg. Data expressed as 
mean±SD, n=3. 
 
Figure 4. Influence of the camptothecin/HP-β-CD ratio on both the drug loading 
(continuous line, left axis) and the encapsulation efficiency (dotted line, right 
axis) of the resulting nanoparticles. Experimental conditions: polymer 100 mg; 
no incubation time after the mixing of the three compounds in acetone (polymer, 
oligosaccharide and drug). Data expressed as mean±SD, n=3. 
 
Figure 5. Scanning electron microscopy (SEM) of freeze-dried poly(anhydride) 
nanoparticles. SPCD-NP: CPT-loaded nanoparticles containing SP-β-CD; 
HPCD-NP: CPT-loaded nanoparticles containing HP-β-CD; MCD-NP: CPT-
loaded nanoparticles containing M-β-CD. 
 
Figure 6. Camptothecin release profile from poly(anhydride) nanoparticles 
containing cyclodextrins (SPCD-NP, HPCD-NP, MCD-NP) after incubation in 
simulated gastric fluid (0-2 h) and simulated intestinal fluid (2-18 h) under sink 
conditions at 37ºC. Data expressed as mean±SD, n=3. SPCD-NP: CPT-loaded 
nanoparticles containing SP-β-CD; HPCD-NP: CPT-loaded nanoparticles 
containing HP-β-CD; MCD-NP: CPT-loaded nanoparticles containing M-β-CD. 
 
Figure 7. Concentration-time profile of CPT in male Wistar rats after a single 
intravenous dose of the drug formulated as aqueous suspension (1 mg/kg). 
Data expressed as mean (±SD), n=6. 
 
Figure 8. Concentration-time profile of CPT in male Wistar rats after a single 
oral dose of the suspension (1 mg/kg) or HPCD-NP (1 mg/kg or 5 mg/kg). Data 
expressed as mean (±SD), n=6. 
 
Figure 9. Hematological (A) and biochemical (B) parameters of blood in Wistar 
male rats 48 hours after administration of a single dose of camptothecin as 
suspension (intravenously, CPT iv 1 mg/kg, or nanoparticles (HPCD-NP 5 
mg/kg).  Data expressed as mean (±SD). (n=6). NR: normal rats; WBC: white 
blood cells; RBC: red blood cells; HGB: hemoglobin; HCT: hematocrit; AST: 
aspartate aminotransferase; ALT: alanine transaminase; Urea: urea nitrogen. 
  
   
  
  
  
  
  
 
  
  
 
  
  
  
  
 
 
 
 
 
  
  
 
 
  
  
 
 
  
Table 1. Apparent stability constants (Kc), complexation efficiencies (CE) and 
maximal solubility at the highest concentration of the oligosaccharide for the 
complexation of CPT with different cyclodextrins in deionised water at 25ºC. β-
CD: β-cyclodextrin; HP-β-CD: hydroxypropyl-β-cyclodextrin; SP-β-CD: 
sulfopropyl-β-cyclodextrin. M-β-CD: methyl-β-cyclodextrin. Data expressed as 
mean±SD, n=3. 
 
Complex Slope 
(x105) 
Kc  
(M-1) 
Maximal CPT 
solubility (mM) 
CE  
(x105) 
CPT / β-CD 273±2 237±18 0.03±0.01 241±5 
CPT / HP-β-CD 151±2 130±20 0.26±0.03 143±2 
CPT / SP-β-CD 114±1 96±15 0.20±0.04 110±2 
CPT / M-β-CD 525±2 453±14 0.96±0.01 524±1 
 
 
 
 
 
  
Table 2. Physico-chemical characterization of poly(anhydride) nanoparticles. 
NP: CPT-loaded nanoparticles in the absence of oligosaccharides; SPCD-NP: 
CPT-loaded nanoparticles containing SP-β-CD; HPCD-NP: CPT-loaded 
nanoparticles containing HP-β-CD; MCD-NP: CPT-loaded nanoparticles 
containing M-β-CD. Data expressed as mean±SD, n=5. 
 
 
Size 
(nm) 
PDI 
Zeta 
potential 
(mV) 
Yield 
(%) 
CPT 
loading 
(µg/mg 
NP) 
EE 
(%) 
NP 130±4 0.10±0.05 -45±2 36±5 2.2±0.3 2.6±0.8 
SPCD-NP 157±4 0.18±0.01 -37±2 51±5 34±2.5 34.7±6.2 
HPCD-NP 148±6 0.15±0.04 -40±1 61±6 50±2.6 61.0±9.5 
MCD-NP 168±5 0.17±0.01 -44±1 58±4 43±3.5 49.9±7.8 
 
 
 
  
Table 3. Analysis of the linear step of the camptothecin release from 
nanoparticles when incubated in simulated intestinal fluid (pH 6.8; pancreatin 
1% w/v). SPCD-NP: CPT-loaded nanoparticles containing SP-β-CD; HPCD-NP: 
CPT-loaded nanoparticles containing HP-β-CD; MCD-NP: CPT-loaded 
nanoparticles containing M-β-CD. 
 
 Zero-order 
KZ0 (h
-1) M0 /M∞ initial R
2 
SP-NP 0.02±0.01 0.61±0.01 0.888 
HP-NP 0.02±0.01 0.58±0.01 0.971 
M-NP 0.02±0.01 0.59±0.01 0.960 
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Table 4. Pharmacokinetic parameters estimated after the intravenous or oral administration of a single dose of camptothecin (1 
mg/kg or 5 mg/kg) formulated as suspension or encapsulated in nanoparticles. HPCD-NP: CPT-loaded nanoparticles containing 
hydroxypropyl-β-cyclodextrin. Data expressed as mean (±SD); (n=6). 
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Dose 
(mg/kg) 
Route 
AUC 
(µg h/mL)  
Cmax 
(µg/mL) 
Tmax 
(h) 
t1/2z 
(h) 
Cl 
(mL/h) 
V 
(mL) 
MRT 
(h) 
 
Fr 
 
CPT 
suspension 
1 iv 0.39±0.12 0.43±0.25 0.01 0.69±0.13 755±289 683±147* 1±0.4 - 
CPT 
suspension 
1 oral 0.38±0.21 0.08±0.02 0.5 1.6 ± 0.8 619±357 1545±414 5.9±1.4 1 
HPCD-NP 1 oral 2.6±1.8* 0.08±0.01 1.5 20.1±6.1** 134±61* 2847±1038 31.0±7.1** 6.9 
HPCD-NP 5 oral 6.2±3.1 0.35±0.05 3.5 16.6±5.5 161±73 3583±745 24.9±9.3 3.3 
AUC: area under the concentration-time curve from time 0 to t h; Cmax: peak plasma concentration; Tmax: time to peak plasma concentration; t1/2z: half-life of the 
terminal phase; Cl: clearance; V: volumen of distribution; MRT: mean residence time; Fr: relative oral bioavailability. *p<0.05, ** p<0.01, HPCD-NP 1 mg/kg vs. 
oral CPT suspension 1 mg/kg.  
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